ArticleGut2020
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.
Abstract readLetterComment
In one paragraph
Article in Gut, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 9 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 9 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.Hepatology international · 2024Pooled it
- Association of Non-Alcoholic Fatty Liver Disease and Metabolic-Associated Fatty Liver Disease with COVID-19-Related Intensive Care Unit Outcomes: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis.World journal of gastroenterology · 2023Pooled it
- COVID-19 Severity and Mortality Among Chronic Liver Disease Patients: A Systematic Review and Meta-Analysis.Preventing chronic disease · 2022Pooled it
- Liver Fibrosis Scores and Hospitalization, Mechanical Ventilation, Severity, and Death in Patients with COVID-19: A Systematic Review and Dose-Response Meta-Analysis.Canadian journal of gastroenterology & hepatology · 2022Pooled it
- The characteristics of gastrointestinal symptoms in patients with severe COVID-19: a systematic review and meta-analysis.Journal of gastroenterology · 2021Pooled it
- Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis.Frontiers in medicine · 2021Pooled it
- WGO Guidance for the Care of Patients With COVID-19 and Liver Disease.Journal of clinical gastroenterology · 2021Guideline
- Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19.Diabetes & metabolic syndromePooled it
- Empagliflozin in the Absence of Diabetes: A Systematic Review of Its Anthropometric and Metabolic Effects in Humans and Animals.International journal of endocrinology · 2026Article
- Prevalence of MASLD and fibrosis assessed by transient elastography in U.S. adolescents: insights from NHANES 2017-2023.Diabetology & metabolic syndrome · 2025Article
- Assessing the consistency of FIB-4, APRI, and GPR in evaluating significant liver fibrosis and cirrhosis in COVID-19 patients with concurrent liver diseases.BMC gastroenterology · 2025Article
- FIB-4 Index Can Predict Mortality in Hospitalized Patients with COVID-19 Infection, Independent of CT Severity Score.Archives of Iranian medicine · 2025Article
- Nonalcoholic Fatty Liver Disease Increases the Risk of Lung Abscess: Findings from a Nationwide Cohort Study.Journal of clinical medicine · 2025Article
- The effect of metabolic dysfunction-associated steatotic liver disease on the disease progression in patients with COVID-19 associated pneumonia.Translational gastroenterology and hepatology · 2025Article
- MAFLD as part of systemic metabolic dysregulation.Hepatology international · 2024Review
- Long-term antibody response after the third dose of inactivated SARS-CoV-2 vaccine in MASLD patients.BMC gastroenterology · 2024Article
- Impact of Non-Alcoholic Fatty Liver Disease on Sepsis Inpatient Outcomes: A Nationwide Sample Analysis (2000-2019).Journal of clinical medicine · 2024Article
- Is Steatotic Liver Disease Related to Poor Outcome in COVID-19-Hospitalized Patients?Journal of clinical medicine · 2024Article
- Impact of metabolic dysfunction-associated steatotic liver disease on COVID-19 hospitalizations: A propensity-matched analysis of the United States.World journal of virology · 2024Article
82 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
Authors and funding
12 authors.
Giovanni TargherDepartment of Medicine, Endocrinology and Metabolism, University of Verona, Verona, Veneto, Italy giovanni.targher@univr.it zhengmh@wmu.edu.cn.ORCID 0000-0002-4325-3900
Alessandro MantovaniDepartment of Medicine, Endocrinology and Metabolism, University of Verona, Verona, Veneto, Italy.
Christopher D ByrneSouthampton National Institute for Health Research Biomedical Research Centre, Southampton General Hospital, Southampton, Hampshire, UK.
Xiao-Bo WangDepartment of Critical Care Medicine, Wenzhou Medical College First Affiliated Hospital, Wenzhou, Zhejiang, China.
Hua-Dong YanDepartment of Hepatology, Ningbo No 2 Hospital, Ningbo, Zhejiang, China.
Qing-Feng SunDepartment of Radiology, Wenzhou Medical University First Affiliated Hospital, Wenzhou, Zhejiang, China.
Ke-Hua PanDepartment of Radiology, Wenzhou Medical University First Affiliated Hospital, Wenzhou, Zhejiang, China.
Kenneth I ZhengNAFLD Research Center, Department of Hepatology, Wenzhou Medical College First Affiliated Hospital, Wenzhou, Zhejiang, China.ORCID 0000-0002-1726-9298
Yong-Ping ChenDepartment of Infection and Liver Diseases, Liver Research Center, Wenzhou Medical College First Affiliated Hospital, Wenzhou, Zhejiang, China.
Mohammed EslamStorr Liver Centre, Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
Jacob GeorgeStorr Liver Centre, Westmead Institute for Medical Research, Westmead, New South Wales, Australia.ORCID 0000-0002-8421-5476
Ming-Hua ZhengNAFLD Research Center, Department of Hepatology, Wenzhou Medical College First Affiliated Hospital, Wenzhou, Zhejiang, China giovanni.targher@univr.it zhengmh@wmu.edu.cn.ORCID 0000-0003-4984-2631
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Coronavirus InfectionsNon-alcoholic Fatty Liver DiseasePandemicsPneumonia, ViralBetacoronavirusCOVID-19FibrosisHumansLiverRetrospective StudiesSARS-CoV-2nonalcoholic steatohepatitis
Identifiers
PMID
32414813What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.